Literature DB >> 3207608

Hodgkin's disease: subsequent primary cancers in relation to treatment.

P Prior1, D J Pope.   

Abstract

A consecutive series of 2,999 patients, diagnosed with Hodgkin's disease (HD) between 1950 and 1979, was assembled from the records of the Birmingham and West Midlands Cancer Registry and followed to the end of 1984. Cohort analyses of subsequent primary cancers among 1,976 patients, surviving one or more years (mean follow-up 6.7 person-years), were carried out in relation to overall treatment by radiotherapy (RT), chemotherapy (CT) or both modalities (CT + RT). Over all sites a 50% increase in risk, relative to the West Midlands population, was found [observed (O) = 65; relative risk (RR) = 1.5; P less than 0.01]. Among patients treated by CT (with or without RT) a significant increase in acute and non-lymphocytic leukaemias was found (O = 6; RR = 30.0; P less than 0.001). The excess risk was of the order of 1 per 1000 patient-years and the cumulative risk was 1.2%. Among solid tumours increased risks, which might be attributable to RT, occurred in the lung (O = 15; RR = 1.6; P less than 0.05), breast (O = 9; RR = 2.2; P less than 0.05) and bone (O = 2; RR = 20.0; P less than 0.01). The excess of skin cancers (O = 13; RR = 2.9; P less than 0.01) occurred mainly within 10 years of treatment with CT. The follow-up period is still insufficient to determine the long-term effect on the incidence of solid tumours with long latent periods from multiple-agent CT which became more frequently used in the early 1970s. A sub-set of these data was analysed over all treatments and the results were contributed to an international study co-ordinated by the International Agency for Research on Cancer, Lyon.

Entities:  

Mesh:

Year:  1988        PMID: 3207608      PMCID: PMC2246798          DOI: 10.1038/bjc.1988.253

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.

Authors:  J C Arseneau; R W Sponzo; D L Levin; L E Schnipper; H Bonner; R C Young; G P Canellos; R E Johnson; V T DeVita
Journal:  N Engl J Med       Date:  1972-11-30       Impact factor: 91.245

2.  Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease.

Authors:  P Valagussa; A Santoro; F Fossati Bellani; F Franchi; A Banfi; G Bonadonna
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

3.  Increased proportion of suppressor/cytotoxic (OKT8+) cells in patients with Hodgkin's disease in long-lasting remission.

Authors:  F Lauria; R Foa; M Gobbi; C Camaschella; P Lusso; D Raspadori; S Tura
Journal:  Cancer       Date:  1983-10-15       Impact factor: 6.860

Review 4.  Impact of Hodgkin's disease upon the immune system.

Authors:  J J Twomey; L Rice
Journal:  Semin Oncol       Date:  1980-06       Impact factor: 4.929

5.  Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease.

Authors:  C P Vanhaelen; R I Fisher
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

6.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; A G Sheil; J Peto; R Doll
Journal:  Br Med J       Date:  1979-12-08

7.  Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.

Authors:  R I Fisher
Journal:  Cancer Treat Rep       Date:  1982-04

8.  Immunity in Hodgkin's disease: status after 5 years' remission.

Authors:  B W Hancock; L Bruce; M D Whitham; I R Dunsmore; A M Ward; J Richmond
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

9.  Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study.

Authors:  M P Coleman; C M Bell; P Fraser
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

View more
  3 in total

1.  [Malignant second tumors in patients after therapy of Hodgkin's disease at the Royal Marsden Hospital].

Authors:  C Glanzmann
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

2.  Subsequent primary cancers in relation to treatment of ovarian cancer.

Authors:  P Prior; D J Pope
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

3.  Second primary malignancies after treatment for malignant lymphoma.

Authors:  A Okines; C S Thomson; C R Radstone; J M Horsman; B W Hancock
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.